目的 探討異位胰腺的臨床特點。方法 回顧性分析解放軍第306醫院1996年10月至2004年12月收治的11例異位胰腺患者的臨床資料。結果 異位胰腺組織位于胃小彎1例，胃竇3例，空腸2例，回腸2例，膽囊壁1例，肝左外葉膽管壁1例，膽總管壁1例。表現為間歇性下消化道出血2例，因反復腹痛、發熱,行鋇餐檢查發現空腸憩室而診斷為空腸憩室炎1例，膽囊息肉樣病變、急性膽囊炎伴膽源性胰腺炎1例，肝膽管結石并反復急性膽管炎1例，膽總管占位性病變1例，余5例無明顯癥狀和體征。11例術前均未考慮異位胰腺，其中10例為腹部手術偶然發現， 1例為胃鏡活檢證實。11例異位胰腺均單發，直徑為0.5～1.8 cm。結論 異位胰腺雖然少見，在胃腸道和膽道疾病的鑒別診斷中對該病應予重視。
Objective To explore the association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and breast cancer risk and to investigate the interaction with menopausal status by meta-analysis. Methods Such databases as The Cochrane Libtary (Issue1, 2010), Pubmed, CBM, CNKI and WanFang Data were searched from the date of their establishment to October, 2010, and the case-control studies of MnSOD Val-9Ala polymorphism and breast cancer risk were collected according to the inclusion and exclusion criteria. Then the quality of the included trials was assessed and meta-analysis was performed by RevMan 4.2.10 software. Results A total of 14 studies involving 17 842 patients were included. The results of meta-analyses showed no significant relation between MnSOD Val-9Ala polymorphism and the breast cancer susceptibility (Val/Ala vs. Val/Val: OR=1.04, 95%CI 0.93 to 1.17; Ala/Ala vs. Val/Val: OR=1.12, 95%CI 0.95 to 1.33; Ala/Ala vs. Val/Ala+Val/Val: OR=1.06, 95%CI 0.93 to 1.20; Val/Ala+ Ala/Ala vs. Val/Val: OR=1.06, 95%CI 0.94 to 1.10). However, in the subgroup analysis, the breast cancer risk significantly increased for premenopausal women (Val/Ala+Ala/Ala vs. Val/Val: OR=1.15, 95%CI 1.01 to1.31). Conclusion This meta-analysis suggests that the MnSOD Val-9Ala polymorphism is not significantly associated with the breast cancer susceptibility, but it may increase the risk of breast cancer in the presence of menopausal state.